The immune checkpoint inhibitor avelumab showed promising antitumor activity and a manageable toxicity profile in patients with platinum-refractory metastatic urothelial carcinoma, according to a new analysis.
The PARP inhibitor talazoparib significantly increased progression-free survival over physician’s choice of therapy in a randomized phase III trial of patients with advanced breast cancer and a germline BRCA mutation.
This video highlights results of a retrospective review that examined survival and other outcomes in younger mantle cell lymphoma (MCL) patients who received consolidation with autologous hematopoietic cell transplant during first remission.
Patient access to NCI Cancer Centers is influenced by a complex mix of cancer center distribution and density, ethnicity, urbanicity, and travel time to care, according to a recently published statistical model.
This video highlights a phase II trial that tested the addition of nivolumab to combination induction chemotherapy of cytarabine and idarubicin for patients with newly diagnosed acute myeloid leukemia.
This article provides a practical perspective on the management of advanced RCC, as well as insight into the current models of risk stratification and ongoing clinical trials. The discussion will focus on the currently available systemic therapies; other strategies that are beyond the scope of this article include active surveillance and metastasectomy.